Literature DB >> 27082375

Irregular menses predicts ovarian cancer: Prospective evidence from the Child Health and Development Studies.

Piera M Cirillo1, Erica T Wang2, Marcelle I Cedars3, Lee-May Chen4, Barbara A Cohn1.   

Abstract

We tested the hypothesis that irregular menstruation predicts lower risk for ovarian cancer, possibly due to less frequent ovulation. We conducted a 50-year prospective study of 15,528 mothers in the Child Health and Development Studies cohort recruited from the Kaiser Foundation Health Plan from 1959 to 1966. Irregular menstruation was classified via medical record and self-report at age 26. We identified 116 cases and 84 deaths due to ovarian cancer through 2011 via linkage to the California Cancer Registry and Vital Statistics. Contrary to expectation, women with irregular menstrual cycles had a higher risk of ovarian cancer incidence and mortality over the 50-year follow-up. Associations increased with age (p <0.05). We observed a 2-fold increased incidence and mortality by age 70 (95% confidence interval [CI] = 1.1, 3.4) rising to a 3-fold increase by age 77 (95% CI = 1.5, 6.7 for incidence; 95% CI = 1.4, 5.9 for mortality). We also found a 3-fold higher risk of mortality for high-grade serous tumors (95% CI = 1.3, 7.6) that did not vary by age. This is the first prospective study to show an association between irregular menstruation and ovarian cancer-we unexpectedly found higher risk for women with irregular cycles. These women are easy to identify and many may have polycystic ovarian syndrome. Classifying high-risk phenotypes such as irregular menstruation creates opportunities to find novel early biomarkers, refine clinical screening protocols and potentially develop new risk reduction strategies. These efforts can lead to earlier detection and better survival for ovarian cancer.
© 2016 UICC.

Entities:  

Keywords:  cohort study; irregular menstrual cycles; ovarian cancer; polycycstic ovarian syndrome; prospective

Mesh:

Year:  2016        PMID: 27082375      PMCID: PMC6917033          DOI: 10.1002/ijc.30144

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.316


  45 in total

Review 1.  Hormonal contraception and risk of endometrial cancer: a systematic review.

Authors:  Alfred O Mueck; Harald Seeger; Thomas Rabe
Journal:  Endocr Relat Cancer       Date:  2010-09-23       Impact factor: 5.678

Review 2.  Clinical practice. Screening for ovarian cancer.

Authors:  Daniel L Clarke-Pearson
Journal:  N Engl J Med       Date:  2009-07-09       Impact factor: 91.245

Review 3.  Old drug, new trick: repurposing metformin for gynecologic cancers?

Authors:  Terri Febbraro; Ernst Lengyel; Iris L Romero
Journal:  Gynecol Oncol       Date:  2014-10-23       Impact factor: 5.482

4.  Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans.

Authors:  Alice S Whittemore; Piera M Cirillo; David Feldman; Barbara A Cohn
Journal:  J Urol       Date:  2005-09       Impact factor: 7.450

5.  Cancer risk and PCOS.

Authors:  Daniel A Dumesic; Rogerio A Lobo
Journal:  Steroids       Date:  2013-04-24       Impact factor: 2.668

6.  The UKCTOCS experience--reasons for hope?

Authors:  Usha Menon; Jatinderpal Kalsi; Ian Jacobs
Journal:  Int J Gynecol Cancer       Date:  2012-05       Impact factor: 3.437

Review 7.  SGO White Paper on ovarian cancer: etiology, screening and surveillance.

Authors:  John O Schorge; Susan C Modesitt; Robert L Coleman; David E Cohn; Noah D Kauff; Linda R Duska; Thomas J Herzog
Journal:  Gynecol Oncol       Date:  2010-08-07       Impact factor: 5.482

8.  Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

Authors:  Usha Menon; Aleksandra Gentry-Maharaj; Rachel Hallett; Andy Ryan; Matthew Burnell; Aarti Sharma; Sara Lewis; Susan Davies; Susan Philpott; Alberto Lopes; Keith Godfrey; David Oram; Jonathan Herod; Karin Williamson; Mourad W Seif; Ian Scott; Tim Mould; Robert Woolas; John Murdoch; Stephen Dobbs; Nazar N Amso; Simon Leeson; Derek Cruickshank; Alistair McGuire; Stuart Campbell; Lesley Fallowfield; Naveena Singh; Anne Dawnay; Steven J Skates; Mahesh Parmar; Ian Jacobs
Journal:  Lancet Oncol       Date:  2009-03-11       Impact factor: 41.316

9.  Fecundability and spontaneous abortions in women with self-reported oligo-amenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study.

Authors:  R Koivunen; A Pouta; S Franks; H Martikainen; U Sovio; A-L Hartikainen; M I McCarthy; A Ruokonen; A Bloigu; M-R Järvelin; L Morin-Papunen
Journal:  Hum Reprod       Date:  2008-06-10       Impact factor: 6.918

Review 10.  Evidence of androgen action in endometrial and ovarian cancers.

Authors:  Douglas A Gibson; Ioannis Simitsidellis; Frances Collins; Philippa T K Saunders
Journal:  Endocr Relat Cancer       Date:  2014-03-12       Impact factor: 5.678

View more
  13 in total

1.  Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium.

Authors:  Holly R Harris; Ana Babic; Penelope M Webb; Christina M Nagle; Susan J Jordan; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Francesmary Modugno; Roberta B Ness; Kirsten B Moysich; Susanne K Kjær; Estrid Høgdall; Allan Jensen; Joellen M Schildkraut; Andrew Berchuck; Daniel W Cramer; Elisa V Bandera; Nicolas Wentzensen; Joanne Kotsopoulos; Steven A Narod; Catherine M Phelan; John R McLaughlin; Hoda Anton-Culver; Argyrios Ziogas; Celeste L Pearce; Anna H Wu; Kathryn L Terry
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-15       Impact factor: 4.254

Review 2.  Female infertility, infertility-associated diagnoses, and comorbidities: a review.

Authors:  Brent Hanson; Erica Johnstone; Jessie Dorais; Bob Silver; C Matthew Peterson; James Hotaling
Journal:  J Assist Reprod Genet       Date:  2016-11-05       Impact factor: 3.412

Review 3.  Urologic conditions associated with malignancy.

Authors:  Eric M Lo; James M Hotaling; Alexander W Pastuszak
Journal:  Urol Oncol       Date:  2019-01-02       Impact factor: 3.498

4.  Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study.

Authors:  H R Harris; L J Titus; D W Cramer; K L Terry
Journal:  Int J Cancer       Date:  2016-10-06       Impact factor: 7.396

Review 5.  Environmental influences on ovarian dysgenesis - developmental windows sensitive to chemical exposures.

Authors:  Hanna Katarina Lilith Johansson; Terje Svingen; Paul A Fowler; Anne Marie Vinggaard; Julie Boberg
Journal:  Nat Rev Endocrinol       Date:  2017-04-28       Impact factor: 43.330

Review 6.  Major clinical research advances in gynecologic cancer in 2016: 10-year special edition.

Authors:  Dong Hoon Suh; Miseon Kim; Kidong Kim; Hak Jae Kim; Kyung Hun Lee; Jae Weon Kim
Journal:  J Gynecol Oncol       Date:  2017-03-24       Impact factor: 4.401

7.  DDT and Breast Cancer: Prospective Study of Induction Time and Susceptibility Windows.

Authors:  Barbara A Cohn; Piera M Cirillo; Mary Beth Terry
Journal:  J Natl Cancer Inst       Date:  2019-08-01       Impact factor: 13.506

8.  Gestational biomarkers of daughter's breast cancer in the Child Health and Development Studies.

Authors:  Piera M Cirillo; Barbara A Cohn
Journal:  Reprod Toxicol       Date:  2019-05-17       Impact factor: 3.421

9.  Assisted reproductive technology and risk of ovarian cancer and borderline tumors in parous women: a population-based cohort study.

Authors:  Frida E Lundberg; Anna L V Johansson; Kenny Rodriguez-Wallberg; Kristina Gemzell-Danielsson; Anastasia N Iliadou
Journal:  Eur J Epidemiol       Date:  2019-08-03       Impact factor: 8.082

10.  Third Trimester Estrogens and Maternal Breast Cancer: Prospective Evidence.

Authors:  Barbara A Cohn; Piera M Cirillo; Bill R Hopper; Pentti K Siiteri
Journal:  J Clin Endocrinol Metab       Date:  2017-10-01       Impact factor: 6.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.